Related Experiment Videos
[Studies on pharmacokinetics of gentamicin in premature infants (author's transl)]
Insights
Gentamicin therapy is effective for preterm and newborn infants, with most achieving therapeutic serum levels. This study confirms adequate gentamicin dosing and highlights a reliable method for monitoring drug concentrations in neonates.
Area of Science:
- Neonatal pharmacology
- Pediatric pharmacokinetics
- Antibiotic therapy
Context:
- Gentamicin is a critical antibiotic for treating neonatal infections.
- Optimizing gentamicin dosage in preterm and low birth weight infants is challenging due to altered pharmacokinetics.
- Therapeutic drug monitoring is essential to ensure efficacy and minimize toxicity.
Purpose:
- To evaluate the adequacy of gentamicin serum concentrations in preterm and newborn infants.
- To assess the pharmacokinetic profile of gentamicin in different gestational age and birth weight groups.
- To determine the suitability of the disc-agarose-diffusion test for routine gentamicin monitoring.
Summary:
- 19 preterm and 2 newborn infants received gentamicin (2.5 mg/kg q12h).
- 74% of post-dose serum levels were within the therapeutic range (3-10 µg/ml).
- No drug accumulation was observed; half-life varied by gestational age and birth weight (5-6.7h vs 2.9h).
- The disc-agarose-diffusion test is a practical method for monitoring gentamicin levels.
Impact:
- Provides evidence for the efficacy of standard gentamicin dosing in neonates.
- Identifies pharmacokinetic differences influencing gentamicin half-life in premature infants.
- Recommends a reliable method for therapeutic drug monitoring, aiding clinical decision-making.
- Contributes to optimizing antibiotic use and improving outcomes in neonatal care.
Abstract:
19 preterm and 2 newborn infants received gentamicin in dosages of 2.5 mg/kg every 12 h. Successive determinations of serum concentrations show, that the levels of gentamicin are adequate for therapy even in preterm infants with low birth weight. Concentrations 30 min after injection (c30min) and base-line-concentrations vary widely. 74% of the 30 min-serum levels are observed within the desired therapeutic range, between 3 and 10 microgram/ml. 16% of the levels measured 30 min after intravenous or intraarterial injection are higher than the known range for potential ototoxicity of 10 microgram/ml. 10% of the 30 min-levels are around 2 microgram/ml, so that the therapeutic efficacy during the following interval of application is doubtful. There is no evidence of accumulation of the drug for periods of treatment up to 7--20 days. The average serum half-life in premature infants with a gestational age of less than 32 weeks and a birth-weight of less than 2000 g is 5--6,7 h. Those with a gestational age of greater than 32 weeks and a birth-weight of greater than 2000 g, and full-term infants show a gentamicin half-life of 2.9h. To determine the actual serum concentration of gentamicin, the rapid and easy disc-agarose-diffusion test using B. subtilis is useful and suitable for routine therapy control.